Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers (A58454) - R15 - Effective Multiple Dates

Date Posted: January 29, 2026

This Billing and Coding Article has been revised under contract numbers: 01111 (CA), 01211 (AS, GU, HI, NMI), 01311 (NV), and 01911 (CA, HI & Territories).

Effective Date: Multiple Dates

Summary of Changes:

Under CPT/HCPCS Codes Group 1: Codes the description was revised for 0569U. This revision is due to the 2026 Annual/Q1 CPT/HCPCS Code Update and is effective 1/1/2026.

Under Article Text subheading Additional Test-specific Indications, Limitations and Instructions revised 3rd sentence to read "the monitoring of response to immune-checkpoint inhibitor therapy for advanced (Signatera) or inoperable/metastatic (Guardant Response) solid tumors". This revision is effective 4/6/2023.

Under ICD-10 Codes that Support Medical Necessity Group 1: Codes added Z85.89 and deleted C79.63. Under ICD-10 Codes that Support Medical Necessity Group 2: Paragraph deleted "(or personal history of a solid tumor but still being treated with ICI therapy". Under ICD-10 Codes that Support Medical Necessity Group 2: Codes deleted C79.63, Z85.01, Z85.020, Z85.028, Z85.030, Z85.038, Z85.040, Z85.048, Z85.05, Z85.060, Z85.068, Z85.07, Z85.09, Z85.110, Z85.118, Z85.12, Z85.21, Z85.22, Z85.230, Z85.238, Z85.29, Z85.3, Z85.41, Z85.42, Z85.43, Z85.44, Z85.46, Z85.47, Z85.48, Z85.4A, Z85.51, Z85.520, Z85.528, Z85.53, Z85.54, Z85.59, Z85.810, Z85.818, Z85.819, Z85.820, Z85.821, Z85.828, Z85.830, Z85.831, Z85.840, Z85.841, Z85.848, Z85.850, and Z85.858. This revision is to remove contradictory verbiage that needed to be revised to be consistent with the policy and is effective 10/1/2022

Visit the Noridian Molecular Diagnostic Services webpage to view the Active MolDX LCDs or access it via the CMS MCD.

Last Updated $dateUtil.getDate( $modifieddate , "MMM dd , yyyy" , $locale , $tzone )